Company news
Alphamab Oncology (HKEX:9966) news
Alphamab Oncology news releases on 6ix. Latest, Sep 28, 2026: Next Day Disclosure Return
Press releases & updates
Next Day Disclosure Return
September 28, 2026
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
April 22, 2026
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
April 22, 2026
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
April 1, 2026
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
March 26, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
March 23, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
March 19, 2026
Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer
March 18, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
March 16, 2026
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE
March 12, 2026
Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer
March 10, 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003
February 14, 2026
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
January 26, 2026
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE
December 29, 2025
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC
December 19, 2025
Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE
December 17, 2025
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
December 10, 2025
Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
November 5, 2025
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC
October 27, 2025
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
October 26, 2025
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022
October 24, 2025
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
October 20, 2025
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
October 20, 2025
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
October 18, 2025
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
September 11, 2025
Alphamab Oncology Reports 2025 Interim Results and Business Highlights
August 28, 2025
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
August 3, 2025
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer
July 31, 2025
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
July 28, 2025
Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting
June 2, 2025
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
April 30, 2025
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
April 29, 2025
Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights
March 25, 2025
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC
March 17, 2025
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
February 27, 2025
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - ABSTRACTS AND E-POSTERS OF RESEARCH UPDATES ON KN046 AND KN026 FOR PRESENTATION AT 2021 ASCO ANNUAL MEETING
May 6, 2021
Alphamab Oncology : (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING
April 27, 2021
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - PRELIMINARY SAFETY TOLERABILITY AND EFFICACY RESULTS OF KN046 IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RELEASED FOR E-POSTER PRESENTATION AT 2021 AACR ANNUAL MEETING
April 12, 2021
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF FINANCIAL OFFICER
March 30, 2021
Alphamab Oncology : Reports Full Year 2020 Financial Results and Business Highlights
March 23, 2021
Alphamab Oncology : Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.
March 9, 2021
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - IND APPROVAL RECEIVED FOR A PHASE II CLINICAL TRIAL OF KN046 IN THE U.S.
March 8, 2021
Alphamab Oncology : Received U.S. FDA IND Approval to Initiate A Phase II Clinical Trial of KN046 For NSCLC in the United States
April 16, 2020
Alphamab Oncology : Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)
March 27, 2020